quarterli updat progress multipl front
analyst certif import disclosur see
quarterli updat progress multipl front
vtgn report fiscal result opex ep vs factset june compani cash cash
equival approxim expect fund oper well encourag continu execut includ
issuanc multipl patent us europ relat multi-cent patient dose elev trial phase adjunct
therapi studi vs placebo data expect smaller nih-sponsor trial slate read late earli
could provid initi poc data believ may offer ketamine-lik efficaci without side effect inconveni
reiter price target
follow updat outlook sale guidanc updat lower end rang va polici revis
occur june later anticip posit chang seen primarili result well-defin expand coverag
germani paralyz popul cover expect realiz higher revenu vs recent expand
access va polici transit patient-bas appeal shorter review time us serv addit contributor regard
restor stroke rehab devic commerci us eu anticip delay restor jv format timwell/realcan
china slightli push anticip receipt equiti investment/minimum purchas
brian jellison step ceo remark tenur includ cultiv strong successor neil hunn broad decentr
corpor cultur consist busi unit oper independ though integr enterpris via intens oper
review support corpor oper execut note previou note consist deal pursuit remain focus
softwar best fit high cash invest averag ebitda margin profil mid-teen d-type
invest high support model private/publ valuat arbitrag
